The DA-EPOCH-R clinical trial in Burkitt’s lymphoma - European Medical Journal

The DA-EPOCH-R clinical trial in Burkitt’s lymphoma

Hematology

Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA, gives an overview of the interim analysis of a multicenter prospective Phase II study of Dose-Adjusted EPOCH-R (NCT01092182), which showed that the vast majority of patients with Burkitt’s Lymphoma achieved complete remission with the DA-EPOCH-R based therapy. The results were presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now